Malgorzata McMasters
Overview
Explore the profile of Malgorzata McMasters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luskin M, Murakami M, Murakami M, Keating J, Keating J, Flamand Y, et al.
Blood
. 2024 Oct;
145(6):577-589.
PMID: 39374521
Dasatinib is an effective treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses...
2.
Cole S, Sarangi S, Einstein D, McMasters M, Alterman R, Bruce J, et al.
Surg Neurol Int
. 2021 Jul;
12:237.
PMID: 34221568
Background: Parkinsonism is a rare complication of non-germinomatous germ cell tumors (NGGCTs) arising from the pineal region. Case Description: We describe a 23-year-old man who presented with Parinaud syndrome, fatigue,...
3.
Steensma D, Wermke M, Klimek V, Greenberg P, Font P, Komrokji R, et al.
Leukemia
. 2021 Jun;
35(12):3542-3550.
PMID: 34172893
We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients...
4.
McMasters M, Blair B, Lazarus H, Alonso C
Blood Rev
. 2020 Nov;
47:100779.
PMID: 33223246
Patients who have hematologic malignancies are at high risk for infections but vaccinations may be effective prophylaxis. The increased infection risk derives from immune defects secondary to malignancy, the classic...
5.
Zwicker J, Wang T, DeAngelo D, Lauw M, Connors J, Falanga A, et al.
J Thromb Haemost
. 2020 Jan;
18(2):278-284.
PMID: 31999063
Venous thromboembolism is a common complication of asparaginase-based chemotherapy regimens for the treatment of acute lymphoblastic leukemia. Thrombosis associated with asparaginase administration poses a number of specific and often clinically...
6.
Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, et al.
Lancet Haematol
. 2019 Dec;
7(2):e122-e133.
PMID: 31837959
Background: Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to assess the activity of...
7.
Nahas M, Stroopinsky D, Rosenblatt J, Cole L, Pyzer A, Anastasiadou E, et al.
Br J Haematol
. 2019 Mar;
185(4):679-690.
PMID: 30828801
Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by an immunosuppressive milieu in the tumour microenvironment (TME) that fosters disease growth and therapeutic resistance. Hypomethylating agents (HMAs) demonstrate...
8.
Politikos I, McMasters M, Bryke C, Avigan D, Boussiotis V
Blood Adv
. 2018 Jun;
2(12):1367-1370.
PMID: 29898877
No abstract available.
9.
Nahas M, Soiffer R, Kim H, Alyea 3rd E, Arnason J, Joyce R, et al.
Blood
. 2018 Mar;
131(25):2836-2845.
PMID: 29549175
Steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. Innovative immunotherapeutic strategies are urgently needed for the treatment of SR-cGVHD. We...
10.
Koreth J, Kim H, Lange P, Poryanda S, Reynolds C, Rai S, et al.
Haematologica
. 2018 Jan;
103(3):522-530.
PMID: 29326124
Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft--host disease incidence, with promising overall and...